Ralph R. Weichselbaum
Director
Ludwig Center at the University of Chicago
Ludwig Institute for Cancer Research
United States of America
Biography
I have devoted my career to translational research in cancer. While a faculty member at Harvard, I defined the role of potentially lethal radiation damage in human tumor cells and the role of this type of DNA repair in radiotherapy. I have recently been investigating the relationship between radiotherapy and immunotherapy and how to optimize both. We are also investigating the clinical and molecular basis of oligometastases of subset metastases curable with localized therapy. We have conducted several clinical trials using stereotactic body radiotherapy for oligometastatic disease and have developed the basis of a microRNA classifier to identify patients with oligometastasis.
Research Interest
Cancer biology, radiotherapy, immunotherapy, therapeutics
Publications
-
Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichselbaum RR, Yamini B. p50 (NF-κB1) is an effector protein in the cytotoxic response to DNA methylation damage. Mol Cell. 2011 Dec 9; 44 (5) :785-96.
-
Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Transl Med. 2013 Feb 20; 5(173): 173sr2.
-
Weichselbaum R, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017 Jan 17. [Epub ahead of print]
